Cell replacement strategies for degenerative and traumatic diseases of the nervous system depend on the functional integration of grafted cells into host neural circuitry, a condition necessary for the propagation of physiological signals and, perhaps, targeting of trophic support to injured neurons. We have recently shown that human neural stem cell (NSC) grafts ameliorate motor neuron disease in SOD1 transgenic rodents. Here we study structural aspects of integration of neuronally differentiated human NSCs in the motor circuitry of SOD1 G93A rats. Human NSCs were grafted into the lumbar protuberance of 8-week-old SOD1 G93A rats; the results were compared to those on control Sprague-Dawley rats. Using pre-embedding immunoelectron microscopy, we found human synaptophysin ( 
MATERIALS AND METHODS
SOD1 G93A breeding SOD1 G93A male rats from our laboratory colony were bred to Tac: N(SD) female rats from Taconic (Germantown, NY). Rats were bred in pairs of one male : one female. Offspring were weaned and genotyped at 21 days of age and positive transgenic pups were used for grafting. The colony was further propagated by breeding male pups of the same litter with the original females as described. All animal care and surgery procedures in this article were carried out according to protocols approved by the Animal Care and Use Committee of the Johns Hopkins Medical Institutions.
Derivation and propagation of human NSCs
Human NSCs were prepared from the cervical-thoracic cord of a single 8-week human fetus as described (Yan et al., 2007) . Tissues were donated by the mother in a manner compliant with NIH and FDA guidelines. Spinal cord tissues free of meninges and dorsal root ganglia were mechanically dissociated into a single cell suspension in serum-free, modified N2 medium and serially expanded in monolayer (Johe et al., 1996) . Growth medium was changed every other day and, on alternate days, 10 ng/mL of bFGF was added to the culture. The first passage was performed at 16 days postplating, a time at which the culture was comprised mostly of dividing NSCs and postmitotic neurons. Dividing cells were harvested by brief treatment with trypsin followed by dissociation and were replated in new precoated plates. Cells were harvested at Ϸ75% confluence that occurred within 5-6 days. The process was repeated for up to 20 passages. Cells from various passages were frozen in the growth medium plus 10% DMSO in liquid nitrogen. Upon thawing, the recovery rate was 80 -95%.
Cells from passages 10 -12 were used in this study. Five to seven days prior to surgery, one cryopreserved vial of cells was thawed, washed, and cultured again. Cells were harvested by enzymatic treatment as described above, washed in buffered saline, transferred to the surgery site on wet ice, and used within 24 hours. Viability of cells under these conditions was greater than 80%. Immediately prior to grafting, the overwhelming majority of human NSCs expressed nestin, whereas Ϸ5% were immunoreactive for PSA-NCAM. Less than 1% of cells expressed the neuronal markers TUJ1 and MAP2 or the astroglial marker GFAP .
Surgical procedures
Surgical procedures were carried out under gas anesthesia (isoflurane:oxygen:nitrous oxide ‫؍‬ 1:33:66) and aseptic conditions. Live or dead NSCs were grafted into the lumbar protuberance (L4 and L5) of 56-day-old SOD1 G93A rats (220 -300 g; mixed gender; n ‫؍‬ 14) or Sprague-Dawley (SD) rats (220 -300 g; mixed gender; n ‫؍‬ 4) mounted on a Kopf spinal stereotaxic unit under microscopic guidance. Dead cells were prepared by 3؋ freezing in liquid nitrogen (-70°F) and then thawing at room temperature; cell death was confirmed by a Trypan Blue uptake assay .
Cell suspensions were grafted with eight injections aimed at the ventral horn on both sides of the spinal cord (1 L with 2 ؋ 10 4 NSCs per injection site, four injection sites per side) using pulled-beveled glass micropipettes connected to 10 L Hamilton microsyringes via silastic tubing. To prevent immune rejection, all rats received FK-506 (1 mg/kg i.p. daily) until euthanized. Four SOD1 rats with live-cell grafts, three SOD1 rats with dead-cell grafts as well as four SD rats with live cell grafts were injected with Bartha-pseudorabies virus (PRV) (a gift from Dr. Patrick Card, PhD, Department of Neuroscience, University of Pittsburgh and Dr. Lynn Enquist, Department of Molecular Biology, Princeton University) and cholera toxin B solution (CTB, Biological Laboratory, CA) into the right hindlimb muscles and sciatic nerve to trace motor circuitry in the spinal cord. The remaining animals were sacrificed after disease onset for electron microscopy (EM) analysis.
Retrograde transneuronal tracing
To assess whether grafted human NSCs can elaborate axons and establish synapses with host neurons, the retrograde transneuronal marker PRV was used to label lumbar motor neurons and nerve cells that innervate them. Fifty L of a Bartha-PRV solution (1 ؋ 10 9 plaque-forming units (pfu)/mL) were injected into the right lateral gastrocnemius muscle/ sciatic nerve of 7 SOD1 G93A rats with live or dead NSCs grafts and four 90-day-old normal SD rats with live NSCs grafts. To directly compare between retrograde and transneuronal transport, after PRV injection 5 L of a 0.25% solution of CTB (diluted with sterilized distilled water) was injected with a new syringe into the same gastrocnemius/sciatic nerve site. Five days after tracer injection, rats were killed by perfusionfixation and spinal cord segments were dissected and stored. At the time of preparation of tissues 40 days after grafting, none of the SOD1 G93A subjects displayed progressive weight loss or decrements in motor strength, i.e., signs of the symptomatic phase of SOD1 G93A-associated motor neuron disease . segments with attached roots and lumbar nerves were further fixed by immersion in the same fixative for an additional 4 hours after removing the dura. Blocks containing the entire grafted area plus 1 mm border above and below were cryoprotected and frozen for further processing. Blocks were sectioned (35 m) at the transverse or sagittal plane. In all cases, representative sections were stained with cresyl violet to study motor neuron cytology and pathology.
In most cases, dual-label immunofluorescence combined the human-specific nuclear protein antibody HNu with another cellular marker and was performed as previously described (Yan et al., 2004) . Briefly, after incubation with the primary antibody overnight at 4°C, sections were treated with secondary antibodies (donkey IgG raised against the species of origin of the primary) labeled with Cy3 or Cy2 (1:200; Jackson ImmunoResearch, West Grove, PA) for 2-4 hours at room temperature. Sections were then counterstained with the fluorescent DNA dye DAPI and coverslipped with DPX. Then sections were studied with a Zeiss Axiophot microscope equipped for epifluorescence and images were captured with a Spot RT Slider digital camera (Diagnostic Instruments, Sterling Heights, MI). If the size of a region of interest was too big to be captured in one frame, a series of adjacent overlapping frames were shot under the same conditions and montaged together with the aid of Adobe PhotoShop 6.0 software (Adobe Systems, San Jose, CA). Confocal microscopic images were captured with a Zeiss LSM 510 inverted confocal microscope (Carl Zeiss, Thornwood, NY). Z-stack images from regions of interest were acquired using LSM software and then optically reconstructed at the X, Y, and Z planes. To eliminate the possibility of nonspecific staining with the PRV antibody, sections from animals with human NSC grafts but without PRV injections were dually stained with PRV and HNu antibodies and served as PRV ICC-negative controls.
Immunoperoxidase staining for human synaptophysin was performed on sections destined for ultrastructural analysis. Briefly, free-floating sections were processed through a series of incubations, with 0.9% phosphate-buffered saline (PBS) washes between steps, as follows: 1.5% hydrogen peroxide for 5 minutes; then incubation in 10% donkey serum for 30 minutes followed by incubation in the primary antibody (mouse antihuman specific synaptophysin monoclonal antibody, 1:500) in 2.5% donkey serum at 4°C overnight; on the second day, incubation in biotinylated anti-IgG (1:200) in 2.5% donkey serum for 2 hours, then treatment with a commercially available avidin-biotin-peroxidase complex (ABC) kit for 30 minutes (Elite ABC kit PK6100, Vector, Burlingame, CA) as per the manufacturer's instructions. Sections were developed with nickel-enhanced 3,3-diaminobenzidine (DAB) and further processed for EM.
Antibody characterization
Primary antibodies used in this study are listed in 
EM of human synaptophysin-labeled synapses in ventral horn
After immunoperoxidase staining for synaptophysin, tissue sections were treated with a solution containing 4% parafor- Serial ultrathin sections were collected on Formvar-coated slotted grids and viewed with a Hitachi H-7600 transmission electron microscope equipped with a 2k ؋ 2k bottom mount AMT-XR-100 CCD camera. Digital images were optimized for brightness/contrast and resolution (set at 600 ppi) with the aid of Adobe PhotoShop 6.0 software. To ascertain that postsynaptic structures contacted by human synaptophysin (؉) terminals belonged to the host, rat motor neurons were identified by their morphology and size (>25 m in soma diameter) and their principal dendrites were identified by tracing back to motor neuron perikarya. The ultrastructural details of synapses originating in human NSC-derived neurons in the spinal cord of SOD1 G93A rat were studied at magnifications 15,000؋ or higher from sites randomly located in the ventral horn, excluding areas of NSCs engraftment. EM micrographs were randomly taken by a researcher who was blinded to the hypothesis being tested. EM micrographs taken at the previous magnifications were used to estimate the frequencies of subtypes of membrane specializations (symmetrical versus asymmetrical) and nature of postsynaptic structure (cell body, dendritic shaft, dendritic spine). Both synapses on identified host structures (motor neurons and their principal dendrites) as well as on unidentified postsynaptic structures were counted. In the latter case, an effort was made to maximize the chance of encountering host (rat) postsynaptic structures: besides avoiding areas of NSCs engraftment, we focused on postsynaptic structures that also had host synapses on them. Host-on-graft contacts are infrequent in these preparations Yan et al., 2007) and, thus, the presence of rat terminals on unidentified dendrites or spines increases the possibility that these postsynaptic structures are of host origin. A total of 150 synapses were counted and percentages of symmetrical versus asymmetrical synapses to identified and unidentified postsynaptic structures were generated.
RESULTS

Human NSC-derived neurons innervate host rat motor neurons and form structurally mature synapses with them
To distinguish between human NSCs and rat host terminals, a human-specific monoclonal antibody against synaptophysin was used. With epifluorescence microscopy, a large number of ChAT (؉) host motor neurons were found to be contacted by human synaptophysin (؉) terminals derived from grafted NSCs (Fig. 1A) . Confocal microscopy further confirmed the apposition of terminals originating in differentiated human NSCs on host motor neurons, both their cell bodies and proximal dendrites (Fig. 1A) . The identity of these motor neurons as being of host origin is deduced from our previous findings that no graft-derived neurons differentiate fully into large motor neurons with the NSC preparations employed in this study (Xu et Based on these light microscopic findings, selected sections from grafted animals were first stained for human synaptophysin and then taken for ultrastructural analysis using standard pre-embedding protocols. Multiple synaptophysin (؉) boutons with synaptic vesicles and membrane specializations were identified in the ventral horn both as en passant and terminal swellings. Many such synaptic structures were found to contact the cell bodies and proximal dendrites of host motor neurons (Fig. 1B-E) .
Human NSC-derived neurons form circuits with themselves and with host neurons in the segmental motor system
To further characterize motor circuits engaging differentiated human NSCs, we injected PRV and CTB into the gastrocnemius muscle/distal sciatic nerve of SOD1 G93A and normal SD rats (Figs. 2, 3, CTB-stained preparations in SOD1 G93A rats showed a robust, but selective labeling of host motor neurons in the dorsolateral motor neuron column on the side of CTB injection ( Fig. 2A) . Host spinal interneurons were left unlabeled, a pattern confirming the expected classical retrograde axonal transport of CTB without further transneuronal transfer. NSC- derived neurons were also left unlabeled, a pattern suggesting that these newly differentiated neurons do not project axons into the distal sciatic nerve and that, in our NSC-grafted subjects, host motor neurons are the only source of direct projections to the periphery.
PRV-stained preparations in transgenic rats show intense labeling, primarily due to PRV immunoreactivity of NSCs grafts both ipsilateral and contralateral to the injection site (Fig. 2B) . Some groups of host neurons in spinal cord other than motor neurons are also consistently labeled: such neurons are in lamina X around the central canal, where host neurons mingle with graft-derived neurons that tend to migrate to that site (Fig. 2D) . PRV ICC performed on sections from animals with human NSC grafts but without PRV injections (negative controls) did not yield any PRV immunoreactivity (Suppl . Fig. 4 ). In addition, many HNu (؉) cells in grafts were not labeled with our PRV antibody (Figs. 2, 3 ). Both patterns demonstrate that our PRV antibody does not label grafted NSCs in a nonspecific fashion. In view of the innervation of host motor neurons by NSC-derived nerve cells documented in the first section of results and a lack of projection of graft-derived neurons outside the cord as shown on CTBstained material, the intense labeling of NSC cells with PRV particles indicates transneuronal retrograde transfer: PRV is first transported from muscle/nerve to host motor neurons and then, via the synaptic terminals of graft-derived neurons on host motor neurons, to the cell bodies of these cells in and around the graft. Further transneuronal transfer via intrinsic connections among graft-derived neurons may result in the intense labeling of the graft that is especially evident in some cases.
The role of synaptic contacts forming between NSC-derived neurons and host motor neurons as transneuronal transfer sites for PRV particles is further supported by data on normal SD rats. These animals do not show spontaneous motor neuron disease and, thus, exclude the confounding variable of motor neuron degeneration that may lead to secondary labeling of graft-derived neurons by PRV particles externalized from dying cells (Brideau et al., 2000) . Patterns of retrograde labeling with CTB and RPV in normal SD rats were similar to those observed in SOD1 G93A rats (Fig. 3) . As in transgenic subjects, CTB labeling was exclusive to large motor neurons in the dorsolateral column (Fig. 3A) . PRV labeling was sparser in motor neurons than in graft-derived cells and the latter were labeled both ipsilateral and contralateral to the RPV injection (Fig. 3B) .
Morphological appearance of synapses forming between NSC-derived and host postsynaptic structures
On the basis of light microscopic observations, many synaptic boutons belonging to graft-derived neurons contacted the cell bodies/proximal dendrites of host motor neurons. In addition to axosomatic synapses on motor neuron bodies, EM revealed that human synaptophysin (؉) terminals also formed axodendritic and axospinous synapses on dendritic shafts and spines traceable to host motor neurons (Fig. 4) . Some graft-derived synaptic boutons were associated with en passant, rather than terminal, swellings (Fig. 4D) . NSC-derived neurons also formed axoaxonal synapses on host synaptic terminals on motor neuron cell bodies (Fig. 4E) (Fig. 4F) .
Besides contacting structures identifiable as belonging to host motor neurons, a large number of graft-derived synaptic boutons were found to contact postsynaptic structures of unclear (host vs. graft) origin and cellular (neuron type) identity (Fig. 5 ). Many such human synaptophysin (؉) boutons coexisted with unlabeled, for example, (rat) synaptic boutons on the shafts and spines of unidentified dendrites (Fig. 5A-C tion of human synaptophysin (؉) synaptic profiles, we divided them into profiles that only had graft-to-host synapses and profiles that also included host-to-host (unlabeled) synapses. As in the case of synapses on identified motor neuron cell bodies and dendrites, the majority of human synaptophysin (؉) terminals on ventral horn dendrites of unknown neuronal origin formed symmetrical synapses (Ϸ65% on unidentified spines and >70% on unidentified dendrite shafts) (Fig. 5D) . These rates were lower than the ones on motor neuron cell bodies and dendrites. Whether the goal is to replace degenerating motor neurons and directly restore information flow in the motor pathways or support injured motor neurons via the expression and release of trophic signals, integration of differentiated human NSCs into the host motor circuit via mature synapses is highly desirable. In addition to transferring key neuroprotective proteins, synapses established between graft-derived neurons and host motor neurons may also modulate motor circuits via the appropriate electric signals; inhibitory neurotransmission, in particular, may contribute to neuroprotection by "buffering" glutamatergic signals (Woo et al., 2007; Sharma, 2007) . Although, in the degenerating ventral horn of G93A SOD1 rats, there is always the possibility that PRV particles can be externalized from dying motor neurons and then transported to graft-derived neurons via fluid-phase endocytosis (Brideau et al., 2000) , the intense labeling of human NSC-derived neurons also in the case of SD rats is indicative of transfer via intact synapses. Further support of a transneuronal, as opposed to retrograde, transport of PRV particles to NSC-derived neurons comes from the timing of the transport and labeling experiments at 90 -95 days of age of G93A transgenic rats, i.e., considerably in advance of the onset of motor neuron disease at 119 -129 days. Even if few motor neurons degenerated at this early stage, it is unlikely that the amount of virus released from these dying cells would be sufficient to infect graftderived neurons (Card et al., 1995 . In addition, most PRV virions released from necrotic neurons under these circumstances would be promptly taken up by surrounding reactive astrocytes (Card et al., 1993 ; Aston-Jones and Card, 2000), and thus removed from the fluid-phase pool available for terminal uptake by graft-derived neurons.
DISCUSSION
Counts of synapses of graft-derived terminals on host structures, both those associated and the ones not apparently associated with host motor neuron, showed that more than two-thirds of these synapses were symmetrical, a morphology generally consistent with inhibitory neurotransmission (Milner et Both the synaptic integration of human NSC-derived neurons and their predominantly inhibitory, putatively GABAergic, neurotransmitter phenotypes help explain their therapeutic effects in motor neuron disease associated with G93A SOD1 mutations in rats and mice, including delays in disease onset and progression and prolongation of the life span of animals . These effects can result from transsynaptic transfer of trophic peptides or via the modulation, by these GABAergic neurons, of the excitotoxic environment in the ventral horn of G93A SOD1 rats, or both. The large number of synapses between human NSC-and host-derived neurons is also remarkable from the point of view of species origin, i.e., the fact that such a large number of "human" synapses can form on the cell body and processes of rat neurons. However, the major significance of this finding is the remarkable malleability of human NSCs and the appropriateness of rodent subjects for further research on the preclinical potential of human NSCs to restore and protect specific neural circuits.
